- Details
- Yair Lotan joins Zachary Klaassen to discuss the 36-month follow-up data of nadofaragene firadenovec for BCG-unresponsive bladder cancer. The phase 3 trial evaluates the long-term efficacy and safety of nadofaragene, an intravesical adenovirus vector administered every three months, in patients with carcinoma in situ and papillary disease. While initial response rates are promising, the discussion...
|
- Details
- Ali Nasrallah discusses the BRAVO study (Bladder Cancer Recurrence Analysis in Veterans and Outcomes). The study examines the real-world impact of blue light cystoscopy versus white light cystoscopy in non-muscle invasive bladder cancer patients within the VA healthcare system. Using data from 1997 to 2021, the research demonstrates significantly reduced recurrence rates at three years with blue l...
|
- Details
- Zachary Klaassen interviews Hiroshi Kitamura about the JCOG1019 study, examining watchful waiting versus BCG therapy in high-grade T1 bladder cancer patients with no residual tumor after second TUR. Dr. Kitamura explains the trial design and key results, highlighting that watchful waiting demonstrates non-inferiority to BCG in relapse-free survival for T1 or deeper recurrence. The study shows simi...
|
- Details
- Laura Bukavina joins Ashish Kamat to discuss the cancer microbiome and nutrition session at the BCAN Think Tank. Dr. Bukavina discusses key presentations on fecal microbiota transplants (FMT) in cancer treatment, highlighting promising results in lung cancer and melanoma. She emphasizes the potential of FMT to improve treatment responses and reduce toxicity. The conversation covers NCI funding opp...
|
- Details
- Zach Klaassen interviews Michiel Van der Heijden about the SunRISe-1 trial, which evaluates TAR-200 with or without cetrelimab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Dr. Van der Heijden discusses the trial design and results, highlighting TAR-200 monotherapy's impressive complete response rate of 83.5% and 12-month complete response rate of 57%. He emphasizes the favorab...
|
- Details
- Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and the VOLGA trial exploring ctDNA clearance as a biomarker. Dr. De Santis highlights the promising results of TAR-200, a novel gemcitabine intravesical system, which shows high complete...
|
- Details
- David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology. He outlines ongoing collaborations between cooperative groups and industry partners to develop and validate AI tools for cancer diagnosis and treatment prediction. Dr. McConkey emphasizes the importance of open access data, quality control, and rigorous validation in AI re...
|
- Details
- Roger Li discusses findings from a patient panel at the BCAN Think Tank, focusing on decision-making in BCG-unresponsive and muscle-invasive bladder cancer treatment. He emphasizes the emotional journey patients undergo and the importance of empowering them with information. Dr. Li highlights several patient stories, demonstrating diverse treatment choices ranging from bladder-sparing approaches t...
|
- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
- Details
- Francesco Soria discusses a study validating the IBCG scoring system for intermediate-risk bladder cancer. He explains the heterogeneity of this risk group and the need for better stratification. Soria describes the IBCG model, which uses five risk factors to divide patients into three subgroups. The study validates this model using a large European cohort, showing significant differences in recur...
|
